|Min SIP Amount||Not Supported|
|NAV||₹21.08 (18 Jun 2021)|
|Fund Started||31 Mar 2016|
|Fund Size||₹57 Cr|
|Gland Pharma Ltd.||Healthcare||Equity||6.4%|
|Cholamandalam Investment & Finance Co. Ltd.||Financial||Equity||6.3%|
|HDFC Bank Ltd.||Financial||Equity||5.7%|
|Reliance Industries Ltd.||Energy||Equity||5.5%|
|Tube Investments Of India Ltd.||Automobile||Equity||5.4%|
|Elgi Equipments Ltd.||Engineering||Equity||5.4%|
|Kennametal India Ltd.||Engineering||Equity||5.3%|
|Larsen & Toubro Ltd.||Construction||Equity||5.2%|
|ICICI Bank Ltd.||Financial||Equity||5.1%|
|Camlin Fine Sciences Ltd.||Chemicals||Equity||5.0%|
SBI Long Term Advantage Fund Series III Regular Growth is a Equity Mutual Fund Scheme launched by SBI Mutual Fund. This scheme was made available to investors on 31 Mar 2016. Rama Iyer Srinivasan, Nidhi Chawla is the Current Fund Manager of SBI Long Term Advantage Fund Series III Regular Growth fund.The fund currently has an Asset Under Management(AUM) of ₹57 Cr and the Latest NAV as of 18 Jun 2021 is ₹21.08.
The SBI Long Term Advantage Fund Series III Regular Growth is rated Very High risk.
The scheme seeks to generate capital appreciation over a period of ten years by investing predominantly in equity and equity-related instruments of companies along with income tax benefit.